InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.250 0.035 (16.28%)+
Announcement
Release
30 Apr 2026 9:13AM
Price at Release
$0.215
Full Release
download
Summary
Dimerix Limited has released its quarterly activities report and Appendix 4C for the period ending March 31, 2026, highlighting significant progress in its clinical trials and financial strategies. The company has completed adult recruitment for its ACTION3 Phase 3 trial in FSGS, ensuring that the trial is powered to demonstrate efficacy in reducing proteinuria. Despite considering accelerated approval, Dimerix has opted to continue the trial to the final endpoint, aligning with FDA feedback. Financially, Dimerix is in discussions for up to US$50 million in non-dilutive funding and has appointed Mike Tonroe as the CFO and company secretary, strengthening its leadership team.
Key Points
  • Dimerix appoints Mike Tonroe as inaugural in-house CFO and company secretary.
  • Dimerix is in late-stage discussions for non-dilutive funding up to US$50 million.
  • The ACTION3 Phase 3 trial for FSGS has completed adult recruitment.
  • The trial is statistically powered to demonstrate proteinuria reduction.
  • Dimerix and partners decided to continue the trial to the final endpoint for better regulatory success.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.